Gossamer Bio Inc (GOSS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $67.10M
Last updated: Nov 17, 2026 at 11:05 AM ET
Gossamer Bio Inc (GOSS) Stock Forecast
Analysts expect Gossamer Bio (GOSS) to earn -$18.01 per share in the fiscal year ending Dec 31, 2026, on revenue of $40.51M. Of 8 analysts, 4 rate the stock Buy or Strong Buy, 3 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 2.63, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 50% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 12.5% |
| Buy | 3 | 37.5% |
| Hold | 3 | 37.5% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 12.5% |
- Consensus
- Hold
- Total analysts
- 8
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates fall 58.7%.
- Fiscal year ending Dec 31, 2026
- -$18.01
- EPS consensus, revenue $40.51M
- Fiscal year ending Dec 31, 2027
- -$15.61
- EPS consensus, revenue $16.73M
- Next report
- Mar 15, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$18.01 | -$23.08 to -$11.20 | 4 | $40.51M | $26.19M to $68.40M | 7 |
| Dec 31, 2027 | -$15.61 | -$28.80 to -$2.88 | 5 | $16.73M | N/A | 7 |
Quarterly Estimates
The EPS consensus falls from -$3.23 for the quarter ending Dec 31, 2026 to -$6.39 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$3.23 | -$6.13 to -$1.60 | 9 | $3.59M | N/A | 9 |
| Mar 31, 2027 | -$6.39 | -$7.20 to -$5.60 | 3 | $840000 | N/A | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$34.08.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$18.01 | -$16.32 | -$14.40 | -$31.91 | -$34.08 | N/A |
| Fiscal year ending Dec 31, 2027 | -$15.61 | -$15.62 | -$14.48 | -$7.38 | -$7.73 | N/A |
| Quarter ending Mar 31, 2027 | -$6.39 | -$6.40 | -$5.60 | -$5.07 | -$5.07 | N/A |
Frequently Asked Questions About GOSS
What is the GOSS stock forecast?
Consensus analyst estimates put Gossamer Bio's EPS at -$18.01 for the fiscal year ending Dec 31, 2026, on revenue of $40.51M. The consensus rating from 8 analysts is Hold.
How do analysts rate GOSS stock?
Of 8 analysts covering Gossamer Bio, 1 rates it Strong Buy, 3 Buy, 3 Hold, 0 Sell and 1 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from GOSS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$18.01, with estimates from -$23.08 to -$11.20 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$15.61, with estimates from -$28.80 to -$2.88 from 5 analysts.
What revenue do analysts expect from Gossamer Bio next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $40.51M, with estimates from $26.19M to $68.40M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $16.73M.
How many analysts cover GOSS?
8 analysts rate Gossamer Bio stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
GOSS pages: Overview, Earnings, Forecast, Financials, Competitors